Mazdutide vs Survodutide: Dual GLP-1/Glucagon Agonist Research

Mechanism: Dual GLP-1 and Glucagon Receptor Agonism

Both compounds activate GLP-1 and glucagon receptors simultaneously. GLP-1 receptor activation promotes insulin secretion, delays gastric emptying, and reduces appetite. Glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure—a pathway not engaged by GLP-1-only compounds such as semaglutide.

This dual-receptor strategy aims to combine the glucose-lowering and satiety effects of GLP-1 with glucagon receptor signaling effects observed in trials. Early preclinical work suggested oxyntomodulin (a natural dual agonist) as proof-of-concept; synthetic analogs like mazdutide and survodutide were engineered for pharmacokinetic optimization and once-weekly dosing.

Clinical Trial Evidence

Mazdutide: GLORY-1 Phase 3 Study

The GLORY-1 trial enrolled 610 Chinese adults aged 18–75 with a BMI of at least 28, or 24 to less than 28 plus at least one weight-related coexisting condition. Participants received once-weekly subcutaneous mazdutide (4 mg or 6 mg) or placebo for 48 weeks. Primary endpoints were percentage change in body weight and proportion achieving ≥5% weight reduction at week 32.

Key results (treatment-policy estimand):

• At week 32 (primary endpoint): −10.09% (4 mg), −12.55% (6 mg), +0.45% (placebo)
• At week 48: −11.00% (4 mg), −14.01% (6 mg), +0.30% (placebo)
• ≥5% weight reduction: 73.9% (4 mg), 82.0% (6 mg), 10.5% (placebo) at week 32
• ≥15% weight reduction: 35.7% (4 mg), 49.5% (6 mg), 2.0% (placebo) at week 48

Adverse events were primarily gastrointestinal, mostly mild to moderate. Discontinuation due to adverse events occurred in 1.5% (4 mg), 0.5% (6 mg), and 1.0% (placebo). Results were published in the New England Journal of Medicine online May 25, 2025 (June 12, 2025 issue) (DOI:10.1056/NEJMoa2411528).

Survodutide: Phase 2 Obesity Trial

A randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial enrolled 386 participants (aged 18–75 years, BMI ≥27 kg/m², without diabetes) across 43 centers in 12 countries. Participants received subcutaneous survodutide (0.6, 2.4, 3.6, or 4.8 mg) or placebo once-weekly for 46 weeks (20 weeks dose escalation; 26 weeks maintenance). Primary endpoint was percentage change in body weight from baseline to week 46.

Key results (planned treatment analysis):

• Mean weight change at week 46: −6.2% (0.6 mg), −12.5% (2.4 mg), −13.2% (3.6 mg), −14.9% (4.8 mg), −2.8% (placebo)
• Adverse events occurred in 91% of survodutide recipients vs 75% of placebo recipients
• Primarily gastrointestinal: 75% survodutide vs 42% placebo

Results were published in The Lancet Diabetes & Endocrinology in March 2024 (DOI:10.1016/S2213-8587(23)00356-X). Phase 3 SYNCHRONIZE trials are ongoing.

Regulatory Status

Mazdutide: China's National Medical Products Administration (NMPA) approved mazdutide (marketed as Xinermei by Innovent Biologics) in June 2025 for chronic weight management in adults with overweight or obesity, and type 2 diabetes (September 2025). This is the world's first approved dual GLP-1/glucagon receptor agonist for weight loss. The approval followed the Phase 3 GLORY-1 trial.

Survodutide: No regulatory approvals as of October 2026. Boehringer Ingelheim is conducting the Phase 3 SYNCHRONIZE program, which evaluates survodutide in obesity and overweight.

Research-grade availability: Research-grade versions of both compounds are available through research peptide suppliers for laboratory and analytical use. These materials differ from pharmaceutical formulations with respect to manufacturing controls, labeling, and regulatory pathways. Laboratories sourcing research-grade dual agonists must verify vendor documentation matches institutional assay requirements.

Comparison Summary for Laboratory Procurement

When to consider mazdutide: Studies requiring a Phase 3 dataset, regulatory-approved comparator context (NMPA), or interest in GLORY program trial designs. The NEJM publication provides detailed cardiometabolic endpoints and safety data suitable for power calculations.

When to consider survodutide: Early-phase exploration of dual GLP-1/glucagon biology, dose-response modeling (four doses tested in Phase 2), or alignment with Boehringer Ingelheim's ongoing SYNCHRONIZE program endpoints. The Lancet Phase 2 data includes international multi-center enrollment.

Both compounds: Share the same dual-receptor mechanism. Neither is FDA-approved. Direct head-to-head trials have not been published; trial populations, designs, and durations differ. Procurement teams should pair compound selection with specific assay endpoints, institutional QA protocols, and vendor COA documentation.